SPOTLIGHT -
Non-muscle Invasive bladder/urothelial Cancer
Penile/Urethral cancer with inguinal adenopathy
Dr. Eric Klein on genomic testing for genitourinary cancers
“It’s really fascinating how the field is expanding,” Klein says.
Dr. Richard Lee on why it’s “a wonderful time” for BPH treatment
“The take-home message is that for the appropriate patient, each of [these] technologies works well,” says Richard K. Lee, MD, MBA.
Dr. Tward discusses his experience with the Prolaris test for prostate cancer
“It’s an extremely useful tool,” says Jonathan D. Tward, MD, PhD, of the Prolaris test.
Have the AUA’s 2012 vasectomy guidelines affected postprocedure follow-up?
Investigators observed a decline in the number of men obtaining repeat postvasectomy semen analyses.
Book provides multidisciplinary perspectives on pelvic pain
The book incorporates insights from 45 experts across 18 specialties.
Dr. Rena Malik on cystectomy-related litigation
A search of a legal database found 42 cases related to cystectomy over a 30-year period.
Dr. Evan Yu on PSMA-PET imaging in prostate cancer
Yu discusses the background of PSMA-PET imaging, current and emerging PSMA imaging tools/therapeutics, and the future of the novel technique in prostate cancer.
Dr. Bishoy M. Faltas on the role of genomic testing in bladder cancer
“The role of genomic testing in bladder is expanding almost every year,” says Faltas.
Dr. Sumanta K. Pal on cabozantinib in papillary RCC
In the phase 2 SWOG 1500 study, cabozantinib (Cabometyx) significantly improved progression-free survival versus sunitinib (Sutent) in patients with metastatic papillary renal cell carcinoma.
Are urologists counseling patients on smoking cessation?
“Very, very few patients actually had any counseling documented or any medications ordered that would help with smoking cessation,” says Richard S. Matulewicz, MD.
Dr. Thomas Powles explains standard treatment for metastatic urothelial cancer
Treatment following progression on chemotherapy and an immune checkpoint inhibitor remains an unmet medical need.
Dr. Shaakir Hasan discusses disparities in bladder cancer diagnosis and treatment
Shaakir Hasan, DO, discusses socioeconomic characteristics associated with the diagnosis and management of bladder cancer.
Dr. Michael Philip O'Leary on potential risks of penile implant surgery
O’Leary discusses safety related to instillation of the Penuma penile enhancement implant.
Dr. Neal Shore on the future of darolutamide in prostate cancer
Darolutamide is currently approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
Dr. Thomas E. Hutson on results of phase 3 CLEAR trial of pembrolizumab/lenvatinib in RCC
The immunotherapy/TKI combination significantly improved overall survival versus sunitinib.
Prolaris test aids in decision making on multimodal therapy in prostate cancer
“I find [the Prolaris test] to be a very helpful clinical tool,” says Jonathan D. Tward, MD, PhD.
Around the Practice: February 17, 2021
Hear from key opinion leaders in the urology space as they discuss 2 complex cases across the multidisciplinary approach for an incidentally discovered adrenal mass and localized, high-risk prostate cancer with oligometastasis at diagnosis.
Localized, high-risk prostate cancer with oligometastasis at diagnosis
Incidentally discovered adrenal mass
Dr. Mary Samplaski discusses online resources regarding male infertility
“The available information [on] male infertility websites right now is not of good quality,” Samplaski says.
Dr. Stephen A. Boorjian on the next steps with nadofaragene firadenovec in NMIBC
Boorjian anticipates research with nadofaragene firadenovec in settings beyond BCG-unresponsive non-muscle invasive bladder cancer.
Dr. Michael Philip O'Leary discusses penile implant surgery
O’Leary is 1 of 10 surgeons in the United States capable of performing the surgery to install the FDA-cleared Penuma penile enhancement implant.
Dr. Robert J. Motzer on pembrolizumab/lenvatinib survival benefit in frontline RCC
Motzer highlights the overall survival benefit achieved with the combination of the PD-1 inhibitor and the multikinase inhibitor versus standard sunitinib in the phase 3 CLEAR trial.
Dr. Alexander Kutikov on the COVID-19 vaccine and patients with GU cancers
“The biggest risk that our patients face is a severe COVID-19 episode,” says Kutikov.
Dr. Stephen A. Boorjian on the safety and tolerability of nadofaragene firadenovec in BCG-unresponsive NMIBC
“One of the things that distinguishes this treatment is its patient and provider ease of delivery,” says Boorjian.
Dr. Neeraj Agarwal discusses the ongoing phase 3 CONTACT-02 study of atezolizumab/ cabozantinib in mCRPC
The ongoing trial is enrolling patients at 62 locations in the United States and worldwide.
Dr. Guru Sonpavde on results of phase 3b STRONG trial of fixed-dose durvalumab in urinary tract carcinoma
The FDA recently approved a less-frequent, fixed dose of durvalumab at 1500 mg every 4 weeks for use in patients with metastatic urothelial carcinoma.
Dr. Neal Shore on the final results and crossover analysis of pivotal darolutamide trial in nonmetastatic CRPC
The FDA approved darolutamide in July 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer, based on findings from the phase 3 ARAMIS trial.